31.10.2024 12:14:04
|
IDEXX Laboratories Narrows FY24 EPS Outlook Range, But Trims Revenue Forecast - Update
(RTTNews) - While reporting financial results for the third quarter on Thursday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) narrowed its earnings guidance range for the full-year 2024, while trimming revenue outlook.
For fiscal 2024, the company now projects earnings in a range of $10.37 to $10.53 per share on revenues between $3.865 billion and $3.890 billion, with revenue growth of 5.5 to 6.2 percent and organic revenue growth of 5.3 to 6.0 percent.
Previously, the company expected earnings in the range of $10.31 to $10.59 per share on revenues between $3.885 billion and $3.945 billion, with revenue growth and organic revenue growth of 6.2 to 7.8 percent.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $10.56 per share on revenues of $3.92 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
03.02.25 |
Schwacher Wochentag in New York: NASDAQ Composite beendet den Handel im Minus (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 zum Ende des Montagshandels schwächer (finanzen.at) | |
03.02.25 |
Verluste in New York: NASDAQ Composite nachmittags in Rot (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 am Montagnachmittag schwächer (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
03.02.25 |
Zurückhaltung in New York: NASDAQ Composite mittags in Rot (finanzen.at) |
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 444,20 | -1,53% |